Authors: CAIROLI R RIBERA S NOSARI AM MUTI G MONTILLO M SANTOLERI L MORRA E

Citation: R. Cairoli et al., HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE (HD-VP CTX) AS SALVAGE TREATMENT FOR ALL PATIENTS/, Blood, 90(10), 1997, pp. 3811-3811

Authors: FOA P IURLO A ORAZI A SAGLIO G RIBERA S BERTONI F CALDIERA S FORNIER M MAIOLO AT

Citation: P. Foa et al., BIOLOGICAL DETERMINANTS OF LONG-TERM SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED WITH CONVENTIONAL CHEMOTHERAPY, Acta haematologica, 97(3), 1997, pp. 187-188

Authors: FOA P IURLO A RIBERA S DAMILANO I CALDIERA S FORNIER M BERTONI F MAIOLO AT

Citation: P. Foa et al., CHRONIC MYELOID-LEUKEMIA TREATED WITH BUSULFAN - RELATIONSHIP BETWEENTOTAL AMOUNT OF DRUG REQUIRED DURING THE FIRST YEAR OF TREATMENT AND DURATION OF CHRONIC PHASE, Oncology Reports, 3(6), 1996, pp. 1067-1069

Authors: FOA P POMATI M RIBERA S CALDIERA S BERTONI F FORNIER M MAIOLO AT

Citation: P. Foa et al., FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) FOR EVALUATING RESIDUAL DISEASE IN PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOID-LEUKEMIA DURING INTERFERON-ALPHA THERAPY, Oncology Reports, 3(5), 1996, pp. 847-849

Authors: NERI A FRACCHIOLLA NS RADAELLI F BOLETINI A RIBERA S MIGLIORINI C TRECCA D MAIOLO AT

Citation: A. Neri et al., P53 TUMOR-SUPPRESSOR GENE AND RAS ONCOGENES - MOLECULAR ANALYSIS IN THE CHRONIC AND LEUKEMIC PHASES OF ESSENTIAL THROMBOCYTHEMIA, British Journal of Haematology, 93(3), 1996, pp. 670-673

Authors: FOA P MASSARO P RIBERA S IURLO A MEZZANOTTE C GIANDALIA D MAIOLO AT

Citation: P. Foa et al., ROLE OF INTERFERON ALPHA-2A IN THE TREATMENT OF POLYCYTHEMIA-VERA, American journal of hematology, 48(1), 1995, pp. 55-57